N/A N=24 Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
Obesity
Primary: Net Tissue-type Plasminogen Activator (t-PA) Release — 0.24; 0.59; -0.38; 0.29 ng/min/100ml — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
Diphtheria · Tetanus · Pertussis
Primary: Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B®…
Phase 2 N=6 Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
Homozygous Familial Hypercholesterolemia
Primary: LDL-C — -50.94 percentage change in LDL-C
Phase 2 N=260 Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
Hyperlipidemia
Primary: Absolute Change From Baseline in Percent Hepatic Fat — 0.03; 4.72 Percent of Hepatic Fat — p=<0.001
Phase 3 N=29 A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -40.1 Percent Change
N/A N=66 Complex Sleep Apnea Syndrome (CompSAS) Resolution Study
Complex Sleep Apnea Syndrome
Primary: Apnea-hypopnea Index (AHI) Per Polysomnography (PSG) at the End of Treatment Period — 4.4; 9.9 AHI (events/hour)
Phase 3 N=665 Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase — 6.8; 6.7; -3.9; -3.5 units on a scale — p=0.1221
N/A N=4 Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight (in Lbs.) — 24.9 lbs.
Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
Vaccines, Pneumococcal
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 32.1; 30.0; 30.4; 36.7 Percentage of Participants
Phase 2 N=157 AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at 8 Weeks — 2; -42; -16; -37 Percent Change
Phase 3 N=666 Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 94.4; 98.0; 87.3; 92.8…
Phase 4 N=127 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16 — 0.62; 1.01; 2.14; 0.93 Scores on a Scale
Phase 3 N=2,654 Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
Influenza
Primary: Percentages Of Subjects Who Achieved HI Titer ≥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines — 29; 33; 30; 31…
N/A N=64 Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation
Constipation
Primary: Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym) — -0.22; -0.29 units on a scale — p=<0.05
Phase 1 N=223 A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
Herpes Zoster
Primary: Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies — 1.74; 1.64; 3.24; 2.45 Geometric mean fold change